---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-048064"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T03:53:50.217970+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# InMed reduces exercise price of Sabby and Wainwright preferred investment options to $0.80

## Summary
- Sabby options now exercisable at $0.80 (was $2.436) for up to 2,151,478 shares.
- Wainwright options exercise price reduced to $0.80 from $82.50, $20.75, and $3.2013 for 153,236 shares.
- Amendments signed April 21 and April 24, 2026; announced April 27.
- Lower exercise price could lead to exercise and dilution of existing shareholders.

## SEC filing metadata
- accession: 0001213900-26-048064
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390026048064/0001213900-26-048064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390026048064/ea0287728-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-048064
- JSON: https://secwatch.observer/filing/0001213900-26-048064.json
- Plain text: https://secwatch.observer/filing/0001213900-26-048064.txt

## Key facts
- Equity Issuances
  InMed Pharmaceuticals Inc. issued up to 153,236 common shares (on a post-consolidation basis) of warrant to affiliates of H.C. Wainwright & Co., LLC for amended the Wainwright Exercise Prices contained in each Wainwright Preferred Investment Option to $0.80.
  - Security: warrant
  - Shares: up to 153,236 common shares (on a post-consolidation basis)
  - Purchaser: affiliates of H.C. Wainwright & Co., LLC
  - Consideration: amended the Wainwright Exercise Prices contained in each Wainwright Preferred Investment Option to $0.80
  source text: On April 24, 2026, the Company entered into Preferred Investment Option Amending Agreements (the “Wainwright Preferred Investment Option Amending Agreements”) with each Wainwright Party to amend the Wainwright Exercise Prices contained in each Wainwright Preferred Investment Option to $0.80.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390026048064/0001213900-26-048064-index.htm
- Equity Issuances
  InMed Pharmaceuticals Inc. issued up to 2,151,478 common shares of warrant to Sabby Volatility Warrant Master Fund, Ltd. for amended the Sabby Exercise Price contained in each Sabby Preferred Investment Option from $2.436 to $0.80.
  - Security: warrant
  - Shares: up to 2,151,478 common shares
  - Purchaser: Sabby Volatility Warrant Master Fund, Ltd.
  - Consideration: amended the Sabby Exercise Price contained in each Sabby Preferred Investment Option from $2.436 to $0.80
  source text: On April 21, 2026, the Company entered into a Preferred Investment Option Amending Agreement (the “Sabby Preferred Investment Option Amending Agreement”) with Sabby to amend the Sabby Exercise Price contained in each Sabby Preferred Investment Option from $2.436 to $0.80.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390026048064/0001213900-26-048064-index.htm
- Material Agreements
  InMed Pharmaceuticals Inc. amended Sabby Preferred Investment Option Amending Agreement with Sabby Volatility Warrant Master Fund, Ltd. (effective 2026-04-21).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: Sabby Volatility Warrant Master Fund, Ltd.
  - Effective: 2026-04-21
  source text: On April 21, 2026, the Company entered into a Preferred Investment Option Amending Agreement (the “Sabby Preferred Investment Option Amending Agreement”) with Sabby to amend the Sabby Exercise Price contained in each Sabby Preferred Investment Option from $2.436 to $0.80.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390026048064/0001213900-26-048064-index.htm
- Material Agreements
  InMed Pharmaceuticals Inc. amended Wainwright Preferred Investment Option Amending Agreements with affiliates of H.C. Wainwright & Co., LLC (effective 2026-04-24).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: affiliates of H.C. Wainwright & Co., LLC
  - Effective: 2026-04-24
  source text: On April 24, 2026, the Company entered into Preferred Investment Option Amending Agreements (the “Wainwright Preferred Investment Option Amending Agreements”) with each Wainwright Party to amend the Wainwright Exercise Prices contained in each Wainwright Preferred Investment Option to $0.80.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390026048064/0001213900-26-048064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.